

J M Smith Among World's Most Ethical Companies

The J M Smith Corporation, parent company of **Smith Drug Company, Smith Premiere Services, QS/1, and Integral Solutions**, has been listed as among the 2010 World's Most Ethical Companies. The survey is researched and compiled by the **Ethisphere Institute**, an organization that started compiling the list four years ago.

"The competition for the World's Most Ethical Companies was the stron-

gest it has ever been, with a record number of organizations vying for this distinguished honor," said Alex Brigham, executive director of the Ethisphere Institute.

The J M Smith Corporation joins more than two dozen first time recipients, including Ford Motor Company, Adobe Systems, and Campbell Soup Company.

J M Smith made the ranking under the Healthcare category.

"We have always taken pride in doing the right thing," said Bill Cobb, CEO of the J M Smith Corporation. "It is certainly an honor to be recognized for a philosophy that has driven our company for decades."

The Ethisphere Institute looked at companies in more than 100 countries and 36 industries. The methodology for the World's Most Ethical Companies includes reviewing codes of ethics,



litigation and regulatory infraction histories; evaluating the investment in innovation and sustainable business practices; looking at activities designed to improve corporate citizenship; and studying nominations from senior executives, industry peers, suppliers and customers.

"We are pleased to join the ranks of other South Carolina companies who made the list, including Milliken and Company and Fluor," Cobb added.

To read about the methodology and view the complete list of the 2010 World's Most Ethical Companies, visit www.ethisphere.com/wme-2010. The World's Most Ethical Companies are also featured in the Q1 issue of the quarterly magazine *Ethisphere*, which was released March 29. 



Mylan Announces Two Settlement Agreements

Mylan Inc. reports it has entered into settlement agreements with **Takeda Pharmaceutical Co.** related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone Hydrochloride (HCl) and Metformin HCl Tablets, and Actos, 15 mg, 30 mg and 45 mg, known generically as Pioglitazone HCl Tablets.

Actoplus Met

Mylan subsidiary Mylan Pharmaceuticals Inc. was the first company to submit a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification to the U.S. FDA for Actoplus Met and believes it will be eligible for

180 days of marketing exclusivity upon commercial marketing of the product, as provided under the provisions of the 1984 Hatch Waxman Act.

Pursuant to the settlement agreement, Mylan will have the right to market Pioglitazone HCl and Metformin HCl in the U.S. on Dec. 14, 2012, or earlier, under certain circumstances. Actoplus Met had 2009 U.S. sales of \$459 million, according to IMS Health.

Actos

The company also was one of the first companies to submit a substantially complete ANDA containing a Paragraph IV certification to the FDA for Actos and believes it will be eligible for 180 days of shared marketing exclusivity upon commercial marketing of the product.

Pursuant to the settlement agreement, Mylan will have the right to market Pioglitazone HCl in the U.S. on Aug. 17, 2012, or earlier, under certain circumstances. Actos had 2009 U.S. sales of \$3.4 billion, according to IMS Health.

Additional details of both agreements remain confidential and remain subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Currently, Mylan reports it has 142 ANDAs pending U.S. Food and Drug Administration approval representing \$93.8 billion in annual brand sales; 40 of these pending ANDAs are potential first-to-file opportunities, representing \$20 billion in annual brand sales for the 12 months ending Dec. 31, 2010, according to IMS Health. 